TrialClinical cancer research : an official journal of the American Association for Cancer Research2019

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.

Jacob P Laubach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.